The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109006200 · Cited by 152
RetractedContinuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis
Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., & Greenberg, M. E. (1995) · Science · doi:10.1126/science.270.5240.1326 · Cited by 5,287
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · cited 6×
“…and NF-kB pathways (Lee et al., 1999; Chen C et al., 2000; Chen Q et al., 2000; Manna et al., 2000; Sevilla et al., 2001; Dixit and Mak, 2002; Ghosh and Karin, 2002; Karin and Lin, 2002) formulating the hypothesis of the subsequent studies that entails rituximab may inhibit the constitutive…”
BackgroundInfluentialBcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“In February 2004, the food and drug administration (FDA) approved bevacizumab, antivascular endothelial growth factor (VEGF) mAb as a first-lime therapy for metastatic colorectal cancer, which is the first therapeutic to target tumor angiogenesis (Ferrara et al., 2004).”
BackgroundThe Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,431
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“STAT3 is constitutively activated in a variety of tumor cells (Bowman et al., 2000).”
BackgroundBcl-2 inhibition of neural death: decreased generation of reactive oxygen species
Kane, D., Sarafian, T., Anton, R., Hahn, H., Gralla, E., Valentine, J., Ord, T., & Bredesen, D. (1993) · Science · doi:10.1126/science.8235659 · Cited by 1,671
MAP Kinases in the Immune Response
Dong, C., Davis, R. J., & Flavell, R. A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091301.131133 · Cited by 1,662
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Mitogen-activated protein kinases in apoptosis regulation
Wada, T., & Penninger, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207556 · Cited by 1,432 · cited 1×
“Molecular mechanisms of rituximab resistance Deregulation of signal transduction pathways such as the NF-kB, MAPKs, JAK/STAT, AKT/PI3 kinase, or aberrant expression of the signaling molecules can contribute to the acquired chemoresistance (Pommier et al., 2004; Wada and Penninger, 2004).”
BackgroundInduction of Apoptosis by Cancer Chemotherapy
Kaufmann, S. H., & Earnshaw, W. C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4838 · Cited by 1,266
Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., & Gerritsen, M. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21096 · Cited by 1,053
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Lin, Y.-Z., Yao, S., Veach, R. A., Torgerson, T. R., & Hawiger, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14255 · Cited by 918
The Natural History of Initially Untreated Low-Grade Non-Hodgkin's Lymphomas
Horning, S. J., & Rosenberg, S. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412063112303 · Cited by 909
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP
Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 893
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-x L
Chen, C., Edelstein, L. C., & Gélinas, C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2687-2695.2000 · Cited by 760
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
Anderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., & Nadler, L. (1984) · Blood · doi:10.1182/blood.v63.6.1424.1424 · Cited by 704
p38-dependent marking of inflammatory genes for increased NF-κB recruitment
Saccani, S., Pantano, S., & Natoli, G. (2002) · Nature Immunology · doi:10.1038/ni748 · Cited by 693
Strasser, A. (1994) · Cell · doi:10.1016/0092-8674(94)90201-1 · Cited by 666
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644 · cited 1×
“Thus, to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to B1 and 1F5 mAbs (Press et al., 1987; Press et al., 1993, 1995; Kaminski et al., 1993, 1996).”
BackgroundEpling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 1×
“…STAT3 to activate antiapoptosis and proliferation-associated proteins such as Bcl-xL, Bcl2, Mcl-1, c-myc, Cyclin D1, and p21WAF 1 is established in various model systems (Bellido et al., 1998; CatlettFalcone et al., 1999; Kiuchi et al., 1999; Sinibaldi et al., 2000; Epling-Burnette et al., 2001).”
BackgroundGolay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 539
Lee, H. H., Dadgostar, H., Cheng, Q., Shu, J., & Cheng, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9136 · Cited by 521
Seto, M., Jaeger, U., Hockett, R. D., Graninger, W., Bennett, S., Goldman, P., & Korsmeyer, S. J. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02791.x · Cited by 485
Baffy, G., Miyashita, T., Williamson, J. R., & Reed, J. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53280-4 · Cited by 482
Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
Tzung, S.-P., Kim, K. M., Basañez, G., Giedt, C. D., Simon, J., Zimmerberg, J., Zhang, K. Y. J., & Hockenbery, D. M. (2001) · Nature Cell Biology · doi:10.1038/35055095 · Cited by 452
Hyperexpression of mitogen-activated protein kinase in human breast cancer.
Sivaraman, V. S., Wang, H., Nuovo, G. J., & Malbon, C. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119309 · Cited by 451
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
Press, O. W., Appelbaum, F., Martin, P. J., Matthews, D. C., Bernstein, I. D., Eary, J. F., Nelp, W. B., Gooley, T., Glenn, S., Porter, B., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92225-3 · Cited by 428
Klein, G., Giovanella, B., Westman, A., Stehlin, J. S., & Mumford, D. (1975) · Intervirology · doi:10.1159/000149930 · Cited by 426
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Expression of bcl-xL can confer a multidrug resistance phenotype
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995) · Blood · doi:10.1182/blood.v86.5.1903.bloodjournal8651903 · Cited by 415 · cited 3×
“Thus, through modulation of apoptosis, Bcl-xL plays a major role in the determination of cellular response to apoptotic stimuli (Minn et al., 1995; Reed, 1995; Amundson et al., 2000; Tudor et al., 2000).”
BackgroundWilson, B. E., Mochon, E., & Boxer, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5546 · Cited by 410
An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Amundson, S. A., Myers, T. G., Scudiero, D. A., Kitada, S., Reed, J. C., & Fornace, A. J. (2000) · PubMed · Cited by 408
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1974 · Cited by 396 · cited 1×
“Thus, to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to B1 and 1F5 mAbs (Press et al., 1987; Press et al., 1993, 1995; Kaminski et al., 1993, 1996).”
BackgroundDemidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394
Self-citationComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Yeung, K., Janosch, P., McFerran, B., Rose, D. W., Mischak, H., Sedivy, J. M., & Kolch, W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3079-3085.2000 · Cited by 389
Yeung, K. C., Rose, D. W., Dhillon, A. S., Yaros, D., Gustafsson, M., Chatterjee, D., McFerran, B., Wyche, J., Kolch, W., & Sedivy, J. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7207-7217.2001 · Cited by 387
STAT3 Is Required for the gp130-mediated Full Activation of the c-myc Gene
Kiuchi, N., Nakajima, K., Ichiba, M., Fukada, T., Narimatsu, M., Mizuno, K., Hibi, M., & Hirano, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.1.63 · Cited by 385
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
Multidrug resistance transporters and modulation
Tan, B., Piwnica-Worms, D., & Ratner, L. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200009000-00011 · Cited by 384
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis
Fu, Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., & Keller, E. T. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.878 · Cited by 364
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Levy, Y., & Brouet, J. C. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116977 · Cited by 340
Domen, J., Gandy, K. L., & Weissman, I. L. (1998) · Blood · doi:10.1182/blood.v91.7.2272 · Cited by 301
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203947 · Cited by 290
Einfeld, D. A., Brown, J. P., Valentine, M. A., Clark, E. A., & Ledbetter, J. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02867.x · Cited by 278
Canfield, S. M., & Morrison, S. L. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.6.1483 · Cited by 266
Harjunpää, Junnikkala, & Meri (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00745.x · Cited by 256
Lee Jr, J., & McCubrey, J. (2002) · Leukemia · doi:10.1038/sj.leu.2402460 · Cited by 251
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor
Blay, J., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J., & Favrot, M. (1993) · Blood · doi:10.1182/blood.v82.7.2169.2169 · Cited by 249
WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene
Mayo, M. W., Wang, C.-Y., Drouin, S. S., Madrid, L. V., Marshall, A. F., Reed, J. C., Weissman, B. E., & Baldwin, A. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.14.3990 · Cited by 247
The mechanisms of action of rituximab in the elimination of tumor cells
Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247
Transcriptional Activation of the p21 Gene by Interleukin-6 Type Cytokines
Bellido, T., O'Brien, C. A., Roberson, P. K., & Manolagas, S. C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.33.21137 · Cited by 224
MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis
MacKeigan, J. P., Collins, T. S., & Ting, J. P.-Y. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000684200 · Cited by 223
Hofmeister, J. K., Cooney, D., & Coggeshall, K. M. (2000) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.2000.0287 · Cited by 222
Dixit, V., & Mak, T. W. (2002) · Cell · doi:10.1016/s0092-8674(02)01166-2 · Cited by 221
Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., & Jurlander, J. (2002) · Blood · doi:10.1182/blood.v99.4.1314 · Cited by 219
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Tedder, T. F., Streuli, M., Schlossman, S. F., & Saito, H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.1.208 · Cited by 216
Histologic conversion in the non-Hodgkin's lymphomas.
Acker, B., Hoppe, R. T., Colby, T. V., Cox, R. S., Kaplan, H. S., & Rosenberg, S. A. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.1.11 · Cited by 213
Gazzinelli, R. T., Makino, M., Chattopadhyay, S. K., Snapper, C. M., Sher, A., Hügin, A. W., & Morse, H. C. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.1.182 · Cited by 208
Ariga, A., Namekawa, J.-I., Matsumoto, N., Inoue, J.-I., & Umezawa, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112063200 · Cited by 206
The discovery of potent cRaf1 kinase inhibitors
Lackey, K., Cory, M., Davis, R., Frye, S. V., Harris, P. A., Hunter, R. N., Jung, D. K., McDonald, O. B., McNutt, R. W., Peel, M. R., et al. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00668-x · Cited by 206
Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Bellosillo, B., Villamor, N., López-Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91005-6 · Cited by 204
Manshouri, T., Do, K.-A., Wang, X., Giles, F. J., O'Brien, S. M., Saffer, H., Thomas, D., Jilani, I., Kantarjian, H. M., Keating, M. J., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1639 · Cited by 204
Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy
Fan, M., & Chambers, T. C. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0214 · Cited by 198
Schuierer, M. M., Bataille, F., Hagan, S., Kolch, W., & Bosserhoff, A.-K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3861 · Cited by 193
Ghetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191
M. Cardarelli, M. Q. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-001-0247-1 · Cited by 189
Jazirehi, A. R., Vega, M. I., Chatterjee, D., Goodglick, L., & Bonavida, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3500 · Cited by 188
Self-citationBannerji, R., Kitada, S., Flinn, I. W., Pearson, M., Young, D., Reed, J. C., & Byrd, J. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.012 · Cited by 178
Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters
Stephanou, A., Brar, B. K., Knight, R. A., & Latchman, D. S. (2000) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400656 · Cited by 174
Molecular Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Nooter, K., & Stoter, G. (1996) · Pathology - Research and Practice · doi:10.1016/s0344-0338(96)80099-9 · Cited by 171
Sarris, A. H., Kliche, K.-O., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., Messina, O., Pugh, W., Hagemeister, F. B., McLaughlin, P., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008301602785 · Cited by 167
Jazirehi, A. R., & Bonavida, B. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.71.3.1 · Cited by 163
Self-citationVega, M. I., Huerta‐Yépez, S., Garbán, H., Jazirehi, A. R., Emmanouilides, C. E., & Bonavida, B. (2004) · Oncogene · doi:10.1038/sj.onc.1207336 · Cited by 160
Self-citationPosttransplant Lymphoproliferative Disorder
Reams, B. D., McAdams, H. P., Howell, D. N., et al. (2003) · CHEST Journal · doi:10.1378/chest.124.4.1242 · Cited by 148
Horning, S. J., Negrin, R. S., Hoppe, R. T., Rosenberg, S. A., Chao, N. J. A., Long, G. D., Brown, B. W., & Blume, K. G. (2001) · Blood · doi:10.1182/blood.v97.2.404 · Cited by 147
Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis
Fujioka, S., Sclabas, G. M., Schmidt, C., Niu, J., Frederick, W., Dong, Q. G., Abbruzzese, J. L., Evans, D. B., Baker, C. H., & Chiao, P. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206323 · Cited by 146
Waldenström macroglobulinaemia
Ghobrial, I. M., Gertz, M. A., & Fonseca, R. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01246-4 · Cited by 145
Yetter, R. A., Buller, R. M. L., Lee, J. S., Elkins, K. L., Mosier, D. E., Fredrickson, T. N., & Morse, H. C. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.2.623 · Cited by 144
Interleukin‐10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl‐2
Cohen, S. B., Crawley, J. B., Kahan, M., Feldmann, M., & Foxwell, B. M. J. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00348.x · Cited by 142
Kennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141
Friedberg, J. W., Neuberg, D. S., Gribben, J. G., Fisher, D. C., Canning, C. M., Koval, M. A., Poor, C. M., Green, L. M., Daley, J. F., Soiffer, R. J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03535.x · Cited by 140
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Jilani, I. B., O'Brien, S. M., Manshuri, T., Thomas, D. A., Thomázy, V. A., Imam, M., Naeem, S., Verstovšek, S., Kantarjian, H. M., Giles, F. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0055 · Cited by 136
Antibody-Targeted Immunotherapy for Treatment of Malignancy
White, C. A., Weaver, R. L., & Grillo-López, A. J. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.125 · Cited by 130
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
Rose, A. L., Smith, B. E., & Maloney, D. G. (2002) · Blood · doi:10.1182/blood.v100.5.1765.h81702001765_1765_1773 · Cited by 129
Mice carrying a CD20 gene disruption
O’Keefe, T. L., Williams, G. T., Davies, S. L., & Neuberger, M. S. (1998) · Immunogenetics · doi:10.1007/s002510050412 · Cited by 129
Polyak, M. J., Tailor, S. H., & Deans, J. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3242 · Cited by 126
Tudor, G., Aguilera, A., Halverson, D. O., Laing, N., & Sausville, E. A. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400688 · Cited by 122
Ghetie, M.-A., Podar, E. M., Ilgen, A., Gordon, B. E., Uhr, J. W., & Vitetta, E. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7509 · Cited by 118
Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation
Watts, R. G., Huang, C., Young, M. R., Li, J. J., Dong, Z., Pennie, W. D., & Colburn, N. H. (1998) · Oncogene · doi:10.1038/sj.onc.1202259 · Cited by 116
Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).
Tedder, T. F., Klejman, G., Schlossman, S. F., & Saito, H. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.7.2560 · Cited by 114
Foran, J. M., Norton, A. J., Micallef, I. N. M., Taussig, D. C., Amess, J. A. L., Rohatiner, A. Z. S., & Lister, T. A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03019.x · Cited by 113
Cheng, Q., Lee, H. H., Li, Y., Parks, T. P., & Cheng, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203861 · Cited by 108
Deans, J. P., Kalt, L., Ledbetter, J. A., Schieven, G. L., Bolen, J. B., & Johnson, P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22632 · Cited by 106
Wang, D., & Richmond, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006115200 · Cited by 102
Deans, J. P., Schieven, G. L., Shu, G. L., Valentine, M. A., Gilliland, L. K., Aruffo, A. A., Clark, E. A., & Ledbetter, J. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.9.4494 · Cited by 98
Ng, C., Zisman, A., & Bonavida, B. (2002) · The Prostate · doi:10.1002/pros.10155 · Cited by 96
Self-citationPhosphorylation of the CD20 Phosphoprotein in Resting B Lymphocytes
Valentine, M. A., Meier, K. E., Rossie, S. S., & Clark, E. A. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60461-2 · Cited by 95
Predominant expression of the long isoform of Bcl‐x (Bcl‐xL) in human lymphomas
Xerri, L., Parc, P., Brousset, P., Schlaifer, D., Hassoun, J., Reed, J. C., Krajewski, S., & Birnbaum, D. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.423958.x · Cited by 94
Newman, R., Alberts, J., Anderson, D. R., Carner, K., Heard, C., Norton, F. L., Raab, R., Reff, M. E., Shuey, S., & Hanna, N. (1992) · Nature Biotechnology · doi:10.1038/nbt1192-1455 · Cited by 87
Bcl-2 family proteins: regulators of chemoresistance in cancer
Reed, J. C. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03551-6 · Cited by 86
Tedder, T. F., Klejman, G., Distèche, C. M., Adler, D. A., Schlossman, S. F., & Saito, H. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.12.4388 · Cited by 85
Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras
Sánchez-Garcı́a, I., & Martı́n-Zanca, D. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0779 · Cited by 84
Weber-Nordt, R., Henschler, R., SchOTT, E. H., Wehinger, J., Behringer, D. M., Mertelsmann, R. H., & Finke, J. (1996) · Blood · doi:10.1182/blood.v88.7.2549.bloodjournal8872549 · Cited by 81
Molecular mechanisms regulating CD19, CD20 and CD22 gene expression
Kehrl, J. H., Riva, A., Wilson, G. L., & Thévenin, C. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90273-9 · Cited by 78
Venugopal, P., Sivaraman, S., Huang, X., et al. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00206-4 · Cited by 77
Role for the Rac1 Exchange Factor Vav in the Signaling Pathways Leading to NK Cell Cytotoxicity
Galandrini, R., Palmieri, G., Piccoli, M., Frati, L., & Santoni, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3148 · Cited by 74
Fregin, A., Rost, S., Wolz, W., Krebsová, A., Müller, C. R., & Oldenburg, J. (2002) · Blood · doi:10.1182/blood-2002-03-0698 · Cited by 72
Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation
Thommesen, J. E., Michaelsen, T. E., Løset, G. Å., Sandlie, I., & Brekke, O. H. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00010-4 · Cited by 71
Stamenkovic, I., & Seed, B. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.167.6.1975 · Cited by 71
Yu, C., Wang, S., Dent, P., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.143 · Cited by 71
Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils
van der Kolk, L., de Haas, M., Grillo-López, A. J., Baars, J. W., & van Oers, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402424 · Cited by 68
Himmelmann, A., Riva, A., Wilson, G. L., Lucas, B. P., Thevenin, C., & Kehrl, J. H. (1997) · Blood · doi:10.1182/blood.v90.10.3984 · Cited by 68
Hazan‐Halevy, I., Seger, R., & Lévy, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12416 · Cited by 64
Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells
Maldonado, V., Meléndez-Zajgla, J., & Ortega, A. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00150-4 · Cited by 64
Thévenin, C., Lucas, B. P., Kozlow, E., & Kehrl, J. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53411-6 · Cited by 63
Emerging information on the use of rituximab in chronic lymphocytic leukemia
Keating, M. J., O'Brien, S. M., & Albitar, M. X. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30142 · Cited by 62
Rituximab in B-Cell chronic lymphocytic leukemia
Lin, T. S., Lucas, M. S., & Byrd, J. C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00239-2 · Cited by 61
Loss of CD20 expression in relapsed lymphomas after rituximab therapy
Haidar, J. H., Shamseddine, A. I., Salem, Z. M. K., et al. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00007.x · Cited by 59
Benjamin, D., Park, C. D., & Sharma, V. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409059591 · Cited by 59
Ng, C., & Bonavida, B. (2002) · Advances in cancer research · doi:10.1016/s0065-230x(02)85005-9 · Cited by 54
Self-citationPolito, L., Bolognesi, A., Tazzari, P. L., Farini, V., Lubelli, C., Zinzani, P. L., Ricci, F., & Stirpe, F. (2004) · Leukemia · doi:10.1038/sj.leu.2403378 · Cited by 52
Current trends in large cell lymphoma
Fisher, R. I., & Shah, P. (2003) · Leukemia · doi:10.1038/sj.leu.2403096 · Cited by 49
Mori, N., & Prager, D. (1997) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1997.tb00970.x · Cited by 47
Genestier, L., Bonnefoy, N., Rouault, J.-P., Flacher, M., & Revillard, J. (1995) · International Immunology · doi:10.1093/intimm/7.4.533 · Cited by 44
Fennell, D. A., Corbo, M., Dean, N. M., Monia, B. P., & Cotter, F. E. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02603.x · Cited by 42
Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab
Dillman, R. O. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00235-5 · Cited by 38
Update on the Proteasome Inhibitor Bortezomibin Hematologic Malignancies
Goy, A. H., & Gilles, F. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.n.003 · Cited by 33
Non-Hodgkin's lymphomas—current status of therapy and future perspectives
Hiddemann, W. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00367-3 · Cited by 22
Current Treatment Options in Aggressive Lymphoma
Marcus, R. E. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001616926 · Cited by 21
Warren, T. L., & Weiner, G. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30147 · Cited by 21
Smith, M. R. (1996) · Current Problems in Cancer · doi:10.1016/s0147-0272(96)80303-5 · Cited by 19
Analysis of cis-acting elements present in the CD20/B1 antigen promoter
Rieckmann, P., Wilson, G. L., Thévenin, C., Hong, J., & Kehrl, J. H. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3994 · Cited by 18
Manna, S. K., Haridas, V., & Aggarwal, B. B. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900050116435 · Cited by 18
Cerny, A., Merino, R., Makino, M., Waldvogel, F. A., Morse, H. C., & Izui, S. (1991) · European Journal of Immunology · doi:10.1002/eji.1830210724 · Cited by 16
Hulett, M. D., Pagler, E., Hornby, J. R., Hogarth, P. M., Eyre, H. J., Baker, E. G., Crawford, J., Sutherland, G. R., Ohms, S., & Parish, C. R. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4088 · Cited by 14
Genomic Dissection Reveals Locus Response to Stress for Mammalian Acetylcholinesterase
Grant, A. D., Shapira, M., & Soreq, H. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1015112407079 · Cited by 6
Treatment advances in non-Hodgkin’s lymphoma
Tan, B. R., & Bartlett, N. L. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.3.451 · Cited by 5
Cited by
Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., & Bartlett, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4405 · Cited by 440
B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
Martin, F., & Chan, A. C. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090517 · Cited by 369
Schulz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk152 · Cited by 362
Fu, K., Weisenburger, D. D., Choi, W. W. L., Perry, K. D., Smith, L. M., Shi, X., Hans, C. P., Greiner, T. C., Bierman, P. J., Bociek, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9277 · Cited by 334
Watanabe, K., Terakura, S., Martens, A. C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402346 · Cited by 284
Metadata
- Authors
- Jazirehi, A. R., & Bonavida, B.
- Venue
- Oncogene
- Published
- 2005-03-24
- Volume
- 24
- Issue
- 13
- Pages
- 2121-2143
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2017009058
- Cited by
- 275
- References
- 170
- FWCI
- 19.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.